Related references
Note: Only part of the references are listed.Mechanism of CFTR correction by type I folding correctors
Karol Fiedorczuk et al.
CELL (2022)
CFTR mRNAs with nonsense codons are degraded by the SMG6-mediated endonucleolytic decay pathway
Edward J. Sanderlin et al.
NATURE COMMUNICATIONS (2022)
Efficient suppression of endogenous CFTR nonsense mutations using anticodon-engineered transfer RNAs
Wooree Ko et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2022)
Targeting G542X CFTR nonsense alleles with ELX-02 restores CFTR function in human-derived intestinal organoids
Daniel K. Crawford et al.
JOURNAL OF CYSTIC FIBROSIS (2021)
Discovery of CFTR modulators for the treatment of cystic fibrosis
Miqueias Lopes-Pacheco et al.
EXPERT OPINION ON DRUG DISCOVERY (2021)
Transcriptome-wide investigation of stop codon readthrough in Saccharomyces cerevisiae
Kotchaphorn Mangkalaphiban et al.
PLOS GENETICS (2021)
Triple Therapy for Cystic Fibrosis Phe508del-Gating and -Residual Function Genotypes
Peter J. Barry et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
A small molecule that induces translational readthrough of CFTR nonsense mutations by eRF1 depletion
Jyoti Sharma et al.
NATURE COMMUNICATIONS (2021)
Screening Readthrough Compounds to Suppress Nonsense Mutations: Possible Application to β-Thalassemia
Monica Borgatti et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Stop codon context influences genome-wide stimulation of termination codon readthrough by aminoglycosides
Jamie R. Wangen et al.
ELIFE (2020)
ELX-02 Generates Protein via Premature Stop Codon Read-Through without Inducing Native Stop Codon Read-Through Proteins
Daniel K. Crawford et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2020)
Translation initiation downstream from annotated start codons in human mRNAs coevolves with the Kozak context
Maria S. Benitez-Cantos et al.
GENOME RESEARCH (2020)
ELX-02: an investigational read-through agent for the treatment of nonsense mutation-related genetic disease
Eitan Kerem
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2020)
Evaluation of both exonic and intronic variants for effects on RNA splicing allows for accurate assessment of the effectiveness of precision therapies
Anya T. Joynt et al.
PLOS GENETICS (2020)
Decreased mRNA and protein stability of W1282X limits response to modulator therapy
M. A. Aksit et al.
JOURNAL OF CYSTIC FIBROSIS (2019)
Engineered transfer RNAs for suppression of premature termination codons
John D. Lueck et al.
NATURE COMMUNICATIONS (2019)
Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele
P. G. Middleton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of ELX-02, a Potential Treatment for Genetic Disorders Caused by Nonsense Mutations, in Healthy Volunteers
Andi Leubitz et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2019)
Functional Assays Are Essential for Interpretation of Missense Variants Associated with Variable Expressivity
Karen S. Raraigh et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2018)
Advances in therapeutic use of a drug-stimulated translational readthrough of premature termination codons
Maciej Dabrowski et al.
MOLECULAR MEDICINE (2018)
Capitalizing on the heterogeneous effects of CFTR nonsense and frameshift variants to inform therapeutic strategy for cystic fibrosis
Neeraj Sharma et al.
PLOS GENETICS (2018)
Residual function of cystic fibrosis mutants predicts response to small molecule CFTR modulators
Sangwoo T. Han et al.
JCI INSIGHT (2018)
Identification of the amino acids inserted during suppression of CFTR nonsense mutations and determination of their functional consequences
Xiaojiao Xue et al.
HUMAN MOLECULAR GENETICS (2017)
Alternative Start Sites Downstream of Non-Sense Mutations Drive Antigen Presentation and Tolerance Induction to C-Terminal Epitopes
Scott N. Ashley et al.
JOURNAL OF IMMUNOLOGY (2017)
Conditional reprogramming and long-term expansion of normal and tumor cells from human biospecimens
Xuefeng Liu et al.
NATURE PROTOCOLS (2017)
Aminoglycoside interactions and impacts on the eukaryotic ribosome
Irina Prokhorova et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Towards the Prevention of Aminoglycoside-Related Hearing Loss
Mary E. O'Sullivan et al.
FRONTIERS IN CELLULAR NEUROSCIENCE (2017)
Plasmid transfection influences the readout of nonsense-mediated mRNA decay reporter assays in human cells
Jennifer V. Gerbracht et al.
SCIENTIFIC REPORTS (2017)
Systematic Computational Identification of Variants That Activate Exonic and Intronic Cryptic Splice Sites
Melissa Lee et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2017)
Pharmacological Rescue of Conditionally Reprogrammed Cystic Fibrosis Bronchial Epithelial Cells
Martina Gentzsch et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2017)
Nonsense-mediated mRNA decay in humans at a glance
Tatsuaki Kurosaki et al.
JOURNAL OF CELL SCIENCE (2016)
Creation and characterization of an airway epithelial cell line for stable expression of CFTR variants
Laura B. Gottschalk et al.
JOURNAL OF CYSTIC FIBROSIS (2016)
Rules of UGA-N decoding by near-cognate tRNAs and analysis of readthrough on short uORFs in yeast
Petra Beznoskova et al.
RNA (2016)
Translational readthrough potential of natural termination codons in eucaryotes - The impact of RNA sequence
Maciej Dabrowski et al.
RNA BIOLOGY (2015)
Therapeutics Based on Stop Codon Readthrough
Kim M. Keeling et al.
ANNUAL REVIEW OF GENOMICS AND HUMAN GENETICS, VOL 15 (2014)
Assessing the residual CFTR gene expression in human nasal epithelium cells bearing CFTR splicing mutations causing cystic fibrosis
Laia Masvidal et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2014)
Experimental Assessment of Splicing Variants Using Expression Minigenes and Comparison with In Silico Predictions
Neeraj Sharma et al.
HUMAN MUTATION (2014)
Quantitative analysis of mammalian translation initiation sites by FACS-seq
William L. Noderer et al.
MOLECULAR SYSTEMS BIOLOGY (2014)
Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial
Elton Kerem et al.
LANCET RESPIRATORY MEDICINE (2014)
Ataluren as an Agent for Therapeutic Nonsense Suppression
Stuart W. Peltz et al.
ANNUAL REVIEW OF MEDICINE, VOL 64 (2013)
Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene
Patrick R. Sosnay et al.
NATURE GENETICS (2013)
ROCK Inhibitor and Feeder Cells Induce the Conditional Reprogramming of Epithelial Cells
Xuefeng Liu et al.
AMERICAN JOURNAL OF PATHOLOGY (2012)
Pharmaceutical therapies to recode nonsense mutations in inherited diseases
Hui-Ling Rose Lee et al.
PHARMACOLOGY & THERAPEUTICS (2012)
Statistical Analysis of Readthrough Levels for Nonsense Mutations in Mammalian Cells Reveals a Major Determinant of Response to Gentamicin
Celia Floquet et al.
PLOS GENETICS (2012)
Ribosome Profiling of Mouse Embryonic Stem Cells Reveals the Complexity and Dynamics of Mammalian Proteomes
Nicholas T. Ingolia et al.
CELL (2011)
New developments in aminoglycoside therapy and ototoxicity
Jing Xie et al.
HEARING RESEARCH (2011)
New insights into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view
Jose M. Lopez-Novoa et al.
KIDNEY INTERNATIONAL (2011)
Rescue of non-sense mutated p53 tumor suppressor gene by aminoglycosides
Celia Floquet et al.
NUCLEIC ACIDS RESEARCH (2011)
Stimulation of stop codon readthrough: frequent presence of an extended 3′ RNA structural element
Andrew E. Firth et al.
NUCLEIC ACIDS RESEARCH (2011)
Mechanism of escape from nonsense-mediated mRNA decay of human β-globin transcripts with nonsense mutations in the first exon
Gabriele Neu-Yilik et al.
RNA (2011)
Aminoglycoside use in cystic fibrosis: therapeutic strategies and toxicity
Andrew Prayle et al.
CURRENT OPINION IN PULMONARY MEDICINE (2010)
Deletion of CFTR Translation Start Site Reveals Functional Isoforms of the Protein in CF Patients
Anabela S. Ramalho et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2009)
A novel translation re-initiation mechanism for the p63 gene revealed by amino-terminal truncating mutations in Rapp-Hodgkin/Hay-Wells-like syndromes
Tuula Rinne et al.
HUMAN MOLECULAR GENETICS (2008)
PTC124 targets genetic disorders caused by nonsense mutations
Ellen M. Welch et al.
NATURE (2007)
Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers
Samit Hirawat et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Applying nonsense-mediated mRNA decay research to the clinic: progress and challenges
Holly A. Kuzmiak et al.
TRENDS IN MOLECULAR MEDICINE (2006)
Molecular mechanism for distinct neurological phenotypes conveyed by allelic truncating mutations
K Inoue et al.
NATURE GENETICS (2004)
Nonsense-mediated mRNA decay: Splicing, translation and mRNP dynamics
LE Maquat
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2004)
The major 5 ' determinant in stop codon read-through involves two adjacent adenines
S Tork et al.
NUCLEIC ACIDS RESEARCH (2004)
When the message goes awry: Disease-producing mutations that influence mRNA content and performance
JT Mendell et al.
CELL (2001)
Long mutant dystrophins and variable phenotypes: evasion of nonsense-mediated decay?
TP Kerr et al.
HUMAN GENETICS (2001)
N-terminal RAG1 frameshift mutations in Omenn's syndrome:: Internal methionine usage leads to partial V(D)J recombination activity and reveals a fundamental role in vivo for the N-terminal domains
S Santagata et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Share Paper
